NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer.

Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer. Front Oncol (2016) 0.79

Genomic and Histopathological Tissue Biomarkers That Predict Radiotherapy Response in Localised Prostate Cancer. Biomed Res Int (2015) 0.77

Hallmarks of cancer: the next generation. Cell (2011) 140.01

Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88

Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72

Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med (2008) 57.29

Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61

The DNA damage response: making it safe to play with knives. Mol Cell (2010) 16.13

Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83

Proteogenomic characterization of human colon and rectal cancer. Nature (2014) 3.61

Integrating copy number polymorphisms into array CGH analysis using a robust HMM. Bioinformatics (2006) 2.50

A stepwise framework for the normalization of array CGH data. BMC Bioinformatics (2005) 2.08

MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res (2010) 1.44

KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res (2011) 1.38

Prostate cancer, version 1.2014. J Natl Compr Canc Netw (2013) 1.32

NBS1 is a prostate cancer susceptibility gene. Cancer Res (2004) 1.24

Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. Cancer (2012) 1.23

Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. Urol Oncol (2014) 1.16

Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression. Cancer Res (2004) 1.13

High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate (2009) 1.08

An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy. Br J Radiol (2014) 1.04

Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer. BJU Int (2012) 1.02

Epigenetic markers of prostate cancer in plasma circulating DNA. Hum Mol Genet (2012) 0.99

Radiosensitivity of human tumour cells is correlated with the induction but not with the repair of DNA double-strand breaks. Br J Cancer (2003) 0.98

NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy. Clin Cancer Res (2011) 0.96

Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: clinical and translational issues. Cancer (2005) 0.94

ATM missense variant P1054R predisposes to prostate cancer. Radiother Oncol (2007) 0.88

TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer. Prostate (2011) 0.88

An inherited NBN mutation is associated with poor prognosis prostate cancer. Br J Cancer (2012) 0.88

The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression. Int J Cancer (2014) 0.83

DNA repair system and prostate cancer progression: the role of NBS1 polymorphism (rs1805794). DNA Cell Biol (2012) 0.83

Pathological predictors for site of local recurrence after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2012) 0.82